EVALUATING THE USE OF DROTRECOGIN ALFA (ACTIVATED) IN THE TREATMENT OF SEVERE SEPSIS IN FRANCE: OVERVIEW OF A 3-YEAR SURVEY PERIOD

被引：0
|
作者：
Cariou, A. [1 ]
Montravers, P. [2 ]
Guidet, B. [3 ]
Martin, C. D. [4 ]
Fillon, F. [5 ]
Granados, D.
Sapin, H. [5 ]
Tcherny-Lessenot, S. [5 ]
Payen, D. [6 ]
机构：
[1] Cochin Hosp, Med Intens Care Unit, Paris, France
[2] Hop Xavier Bichat, Surg Intens Care Unit, Paris, France
[3] St Antoine Hosp, Med Intens Care Unit, Paris, France
[4] North Hosp, Med Intens Care Unit, Marseille, France
[5] Eli Lilly & Co, Dept Med, Suresnes, France
[6] Univ Paris 07, Lariboisiere Univ Hosp, Med Intens Care Unit, Paris, France
来源：
INTENSIVE CARE MEDICINE | 2010年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
0425
引用
收藏
页码：S192 / S192
页数：1
相关论文
共 50 条
  • [31] Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
    Bernard, GR
    Macias, WL
    Joyce, DE
    Williams, MD
    Bailey, J
    Vincent, JL
    [J]. CRITICAL CARE, 2003, 7 (02) : 155 - 163
  • [32] Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany
    Neilson, AR
    Schneider, H
    Chinn, C
    Clouth, J
    Burchardi, H
    [J]. INTENSIVE CARE MEDICINE, 2002, 28 : S161 - S161
  • [33] Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
    Gordon R Bernard
    William L Macias
    David E Joyce
    Mark D Williams
    Joan Bailey
    Jean-Louis Vincent
    [J]. Critical Care, 7
  • [34] Drotrecogin alfa (activated) for severe sepsis: Could we consider a shorter treatment period in patients with a favorable course?
    Ahishakiye, David
    Lorent, Sophie
    De Backer, Daniel
    Gottignies, Philippe
    Vincent, Jean-Louis
    [J]. JOURNAL OF CRITICAL CARE, 2009, 24 (04) : 590 - 594
  • [35] Use of drotrecogin alfa (activated) for severe sepsis in New Jersey acute care hospitals
    Dombrovskiy, Viktor
    Martin, Andrew
    Sunderram, Jagadeeshan
    Paz, Harold
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2006, 63 (12) : 1151 - 1156
  • [36] The results of the national program of drotrecogin alfa (activated) use in patients with severe sepsis in Poland
    Kubler, A
    Durek, G
    Mayzner-Zawadzka, E
    Majak, P
    [J]. CRITICAL CARE MEDICINE, 2005, 33 (12) : A150 - A150
  • [37] Increased survivorship with drotrecogin alfa (activated) in the treatment of severe sepsis: The effect on hospital costs
    Linde-Zwirble, WT
    Clermont, G
    Van Hout, B
    Ball, DE
    Basson, BR
    Angus, DC
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (12) : A1 - A1
  • [38] Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients
    R Launois
    L Riou Franca
    B Guidet
    P Aegerter
    X Huet
    P Meshaka
    P Pinton
    [J]. Critical Care, 6 (Suppl 1):
  • [39] Drotrecogin alfa (activated): implementing institutional guidelines for use and assessing treatment outcomes in patients with severe sepsis.
    Clarke, H
    Barlows, TG
    Machado, C
    Dalin, G
    Prager, R
    [J]. PHARMACOTHERAPY, 2002, 22 (10): : 1374 - 1375
  • [40] Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
    Vincent, Jean-Louis
    O'Brien, James, Jr.
    Wheeler, Arthur
    Wittebole, Xavier
    Garg, Rekha
    Trzaskoma, Benjamin L.
    Sundin, David P.
    [J]. CRITICAL CARE, 2006, 10 (03)
12345